Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JINS HoldingsJNDOF 85 Debt-to-EBITDA is 0.29 as of Feb. 2026, which is 74% below its 10-year median of 1.11. GuruFocus rates JNDOF with a GF Score™ of 85/100 and a GF Value™ of $28.20 (Significantly Overvalued). Among 467 Medical Devices & Instruments companies, JINS Holdings ranks better than 71.09% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for JINS Holdings's Debt-to-EBITDA or its related term are showing as below:
JNDOF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.39 Med: 1.11 Max: 4.38
Current: 0.49
During the past 13 years, the highest Debt-to-EBITDA Ratio of JINS Holdings was 4.38. The lowest was 0.39. And the median was 1.11.
JNDOF's Debt-to-EBITDA is ranked better than 71.09% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs JNDOF: 0.49
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
JINS Holdings Debt-to-EBITDA Related Terms
JINS Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for JINS Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JNDOF vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, JINS Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JINS Holdings Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, JINS Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where JINS Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Feb. 2026) EBITDA data.
JINS Holdings (JNDOF) has a Debt-to-EBITDA of 0.29 as of Feb. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on JINS Holdings. This is 74% below median its historical median of 1.11. Over the past decade, JINS Holdings' Debt-to-EBITDA has ranged from 0.39 to 4.38. According to the industry distribution chart, JINS Holdings ranks #135 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 28.9%.
Is JINS Holdings' Debt-to-EBITDA too high?
JINS Holdings' current Debt-to-EBITDA of 0.29 is 74% below median its 10-year median of 1.11. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 4.38. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. JINS Holdings' value of 0.29 is 81.5% below this industry median. Based on the distribution chart, JINS Holdings ranks #135 out of 467 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, JINS Holdings has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does JINS Holdings' Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, JINS Holdings ranks #135 out of 467 companies for Debt-to-EBITDA. This puts JINS Holdings in the upper half of its industry. The industry median Debt-to-EBITDA is 1.57. JINS Holdings' value of 0.29 is 81.5% below this benchmark. Historically, JINS Holdings' own Debt-to-EBITDA has ranged from 0.39 to 4.38 over the past decade. While the company's 10-year median is 1.11 vs. the industry median of 1.57, JINS Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JINS Holdings's current Debt-to-EBITDA of 0.29 is 81.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on JINS Holdings. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JINS Holdings's current Debt-to-EBITDA is 0.29, which is 74% below median its own 10-year median of 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JINS Holdings stock overvalued right now?
Based on GuruFocus' analysis, JINS Holdings (JNDOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $28.20, compared to a current price of $38.43 — trading 36.3% above its estimated fair value. The current Debt-to-EBITDA is 0.29, which is 74% below median its 10-year median of 1.11 and 81.5% below the Medical Devices & Instruments industry median of 1.57. JINS Holdings' overall GF Score™ is 85/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For JINS Holdings (JNDOF), the current Debt-to-EBITDA is 0.29 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JINS Holdings (JNDOF) Overvalued in 2026?
Based on GuruFocus' analysis, JINS Holdings stock appears to be overvalued.
The current stock price of $38.43 is trading 36.3% above its estimated GF Value™ of $28.20.
GuruFocus considers JINS Holdings to be Significantly Overvalued.
Key valuation signals for JNDOF:
Debt-to-EBITDA: 0.29 (74% below median its 10-year median of 1.11)
GF Value™: $28.20 vs. price of $38.43 (36.3% above fair value)
Industry Position: 81.5% below the Medical Devices & Instruments median (#135 of 467)
No single metric tells the full story. See the JNDOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JINS Holdings Inc is an eyewear retailer that manufactures and sells private-label fashion eyeglasses and sunglasses. It offers prescription eyeglasses and nonprescription fashion or functional eyeglasses. Its inventory is on the shelves, and it charges flat rates with generally no additional charges or options for lens features. Jin has more than 300 stores in Japan as well as locations in China, Taiwan, and the United States. Stores are typically located in high-traffic areas such as shopping centers, malls, and train stations.
85GF Score
Get the complete analysis for JNDOF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JNDOF has been successfully added to your 
